Weight loss drug concept stocks fluctuate and rise, HYBIO increases by over 10%

HYBIO rose over 10%, while Sun Pharma, Kingmed Diagnostics, and Lepu Medical rose over 5%. Baihua Pharmaceutical, Changshan Pharmaceutical, Shengnuo Biotech, Haofan Biotech, and Deyuan Pharmaceutical also followed suit. On the news front, the U.S. FDA has expedited the approval of the supplemental new drug application for its blockbuster therapy Wegovy, intended for the treatment of adult patients with metabolic dysfunction-associated fatty liver disease accompanied by moderate to severe liver fibrosis. As a result, Novo Nordisk's U.S. stock rose over 6% in after-hours trading